利沃多巴吸收的分子变异性和对帕金森病管理的临床影响
Ana Luisa Pedrosa de Menezes1, Bastiaan R Bloem2, Milan Beckers2
1Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Journal of Parkinson's disease
|September 6, 2024
概括
利沃多巴是帕金森病的黄金标准,显示了显著的吸收变化. 本综述探讨了分子机制,临床影响和管理利沃多巴吸收挑战的策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 临床药房 临床药房
背景情况:
- 利沃多巴是帕金森病的主要症状治疗方法.
- 它仍然是黄金标准,尽管它的年龄.
- 了解勒沃多巴的吸收对于有效治疗至关重要.
研究的目的:
- 审查影响勒沃多巴吸收的分子机制.
- 调查勒沃多巴吸收变化的原因和影响.
- 讨论目前和未来的策略来管理勒沃多巴吸收.
主要方法:
- 文献综述侧重于药理动力学和药理动力学研究.
- 对影响药物吸收的分子机制的分析.
- 对莱沃多巴吸收变异性和药物相互作用的临床数据的检查.
主要成果:
- 在勒沃多巴吸收的显著的内部和个人间的变化是常见的.
- 吸收受到复杂的分子机制的影响.
- 药物相互作用可能进一步影响勒沃多巴的生物可用性.
结论:
- 利沃多巴吸收变异性在帕金森病管理中提出了临床挑战.
- 需要进一步研究吸收机制和个性化策略.
- 优化勒沃多巴的吸收可以改善患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
Factors Influencing Drug Absorption: Disease States and Pharmacology
467
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
467
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
104
Factors Influencing Drug Absorption: Pharmaceutical Parameters
123
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
123
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
179
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
179


